Kenichi Yoshimura

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 289 publications

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: April 28, 2026

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies.

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies.

Journal: ESMO gastrointestinal oncology

Published: April 09, 2026

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Journal: International journal of clinical oncology

Published: March 18, 2026

Type 2 inflammation promotes distinct metabolic profiles in chronic rhinosinusitis with nasal polyps.

Type 2 inflammation promotes distinct metabolic profiles in chronic rhinosinusitis with nasal polyps.

Journal: Rhinology

Published: March 09, 2026

Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.

Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.

Journal: Journal of dental research

Published: February 24, 2026

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Journal: JTO clinical and research reports

Published: November 13, 2025

Effectiveness of on-demand acceptance and commitment training for burnout and well-being in Japanese medical students: protocol for a nationwide randomised controlled trial (BEACON Study).

Effectiveness of on-demand acceptance and commitment training for burnout and well-being in Japanese medical students: protocol for a nationwide randomised controlled trial (BEACON Study).

Journal: BMJ open

Published: November 11, 2025

Eppikajutsuto for Treatment of Lymphatic Malformations in Children: A Nonrandomized Clinical Trial.

Eppikajutsuto for Treatment of Lymphatic Malformations in Children: A Nonrandomized Clinical Trial.

Journal: JAMA network open

Published: November 03, 2025

Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma.

Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma.

Journal: Journal of geriatric oncology

Published: November 01, 2025

Left ventricular volume on immediate postmortem computed tomography (CT) (<1 hour) as an indicator of cardiac death: a retrospective pilot study.

Left ventricular volume on immediate postmortem computed tomography (CT) (<1 hour) as an indicator of cardiac death: a retrospective pilot study.

Journal: Clinical radiology

Published: October 17, 2025

Divergent Construction of Polycyclic Frameworks Enabled by Sequential Ru-Catalyzed [2 + 2 + 2] Cycloaddition of Iododiynes and Pd/Norbornene-Mediated Catellani-Type Annulation.

Divergent Construction of Polycyclic Frameworks Enabled by Sequential Ru-Catalyzed [2 + 2 + 2] Cycloaddition of Iododiynes and Pd/Norbornene-Mediated Catellani-Type Annulation.

Journal: Organic letters

Published: October 14, 2025

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 14, 2025

Showing 1-12 of 289

Last Updated: 09/26/2026